Damora Therapeutics (DMRA) shares declined on July 22, 2026.
Reports indicate a competing blood disorder drug from Incyte will likely reach the market one year ahead of Damora’s candidate. Incyte’s treatment also offers a more convenient method of administration.
Investors are weighing these competitive threats against Damora’s future market position. The stock is also facing pressure from profit-taking following a recent significant rally. Additionally, technical choppiness persists due to the company’s recent redomestication.